Clinical Trials

The clinical trials listed below are for informational purposes only and are not endorsed by the AST/Power2Save. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.

Clinical Trials for Kidney Recipients

• Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Adjunctive Treatment For Refractory Antibody-Mediated Rejection (ARMOR) in Adult Renal Transplant Recipients
  Sponsor: CSL Behring
  Organ Type: Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date: Thursday, January 15, 2026
• A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
  Sponsor: Medeor Therapeutics, Inc.
  Organ Type: Kidney
  Ages Accepted: Age ≥18 and ≤70 years
  Genders Accepted: Both male and female
  Expected Study Completion Date: January, 2022

Clinical Trials for Other Organ Types

• Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Monday, November 30, 2020
  Other Requirements
• A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant (RR) to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
  Sponsor: Takeda Pharmaceutical Company Limited
  Organ Type: Hematopoietic Stem Cell Transplant, All organs
  Ages Accepted: ≥12 years of age
  Genders Accepted: Both male and female
  Expected Study Completion Date: Tuesday, September 29, 2020
  Other Requirements
• A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
  Sponsor: Takeda Pharmaceutical Company Limited
  Organ Type: Hematopoietic Stem Cell Transplant
  Ages Accepted: ≥16 years of age
  Genders Accepted: Both male and female
  Expected Study Completion Date: Tuesday, August 13, 2021
  Other Requirements